Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates

Ann Transl Med. 2023 Oct 25;11(11):399. doi: 10.21037/atm-23-314. Epub 2023 Feb 27.

Authors

Natalie K Heater¹, Stephanie Franco¹, Ami Shah²

Affiliations

¹ Department of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
² Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.

No abstract available

Keywords: Breast cancer; antibody drug conjugates; hormone-receptor positive (HR+); sacituzumab govitecan (SG); trastuzumab deruxtecan (T-DXd).

Publication types

Editorial
Comment